Brought to you by 
Novartis gains rights to Cell Therapeutics' Xyotax; rights returned
19 Sep 2014
Executive Summary
Novartis has licensed exclusive worldwide rights to Cell Therapeutics' (developing compounds to treat cancer) Xytotax (poliglumex paclitaxel), a chemotherapeutic in Phase III studies for non-small cell lung cancer (NSCLC) and other types of cancer, including breast, prostate, and ovarian.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis gains rights to Cell Therapeutics' Xyotax; rights returned
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice